Physician profile
Mudit Jain
NPI 1356305601
$29,808.88
in general payments reported to CMS, 2019-2025
37 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $708 · 2021: $980 · 2022: $1,327 · 2023: $1,263 · 2024: $12K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Food and Beverage: $5,059 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,850 · Travel and Lodging: $2,746 · Education: $99.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,680.00 |
| Food and Beverage | $5,058.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,850.00 |
| Travel and Lodging | $2,746.26 |
| Education | $99.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20,860.26 | 2019-2025 | Korlym |
| Medtronic, INC. | $1,237.70 | 2024-2025 | Minimed 780g |
| Novo Nordisk INC | $1,162.78 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $880.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $827.04 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $414.60 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $409.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.87 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $392.72 | 2020-2025 | Repatha, Tepezza, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $325.24 | 2022-2024 | |
| Dexcom, INC. | $320.22 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $309.07 | 2021-2025 | Afrezza |
| Insulet Corporation | $281.13 | 2022-2025 | Omnipod |
| Abbvie INC. | $280.18 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $271.55 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $171.96 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $148.16 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $147.25 | 2023-2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $125.10 | 2024-2025 | |
| Csl Behring | $101.75 | 2024 | Hizentra |
| Xeris Pharmaceuticals, INC. | $93.71 | 2020-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $83.94 | 2022-2024 | Unithroid |
| Horizon Therapeutics Plc | $78.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $73.77 | 2019-2021 | |
| Beta Bionics, INC. | $51.25 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $46.21 | 2022-2025 | Isturisa |
| Esperion Therapeutics, INC. | $34.05 | 2021-2025 | Nexletol |
| Medtronic Minimed, INC. | $32.76 | 2019 | |
| Lifescan, INC. | $28.26 | 2022 | |
| Kyowa Kirin, INC. | $26.22 | 2025 | |
| Neurocrine Biosciences, INC. | $25.82 | 2025 | |
| Eusa Pharma (US) LLC | $23.80 | 2022 | |
| Roche Diabetes Care, INC. | $18.86 | 2020 | |
| Radius Health, INC. | $18.66 | 2019 | |
| Cequr Corporation | $16.67 | 2025 | Cequr Simplicity |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mudit Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.